Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated platform that aims to accelerate enzyme catalyst development for biomanufacturing. The platform merges computational enzyme engineering with hands-on process development to deliver predictable and practical biocatalysis solutions stable at industrial scale. While biocatalysis is an established manufacturing process, a significant gap exists between identifying application opportunities and having suitable enzymes available. Traditional development approaches struggle to meet the speed requirements of iterative product development, and AI addresses this by predicting enzyme candidates, designing enzymes constrained by process parameters, and leveraging molecular features to anticipate performance in advance.
The platform's capabilities are delivered through three specialized service modules: AI-Driven Biocatalysis Solutions, AI-Driven Industrial Biocatalysis, and AI-Driven Green Biocatalysis. The first module provides an end-to-end workflow from target reaction analysis to scale-up characterization, reducing the design-build-test-learn cycle from 12-24 months to 8-12 months for moderately complex targets. The second module bridges lab-scale performance and commercial production, addressing substrate concentration optimization, cofactor regeneration, immobilization, and process analytical technology integration. The third module focuses on sustainability, leveraging enzymatic reactions that occur in aqueous media at room temperature to minimize organic solvent use and waste generation.
The platform's effectiveness was demonstrated in a transaminase engineering case study, where an AI-driven 6D protein engineering framework combined interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five transaminase variants with nine mutations each exhibited high solubility and catalytic stability at 7-liter fermentation scale, converting prochiral ketones to sitagliptin with enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up production. This showcases how AI reduces experimental screening efforts and accelerates the development of efficient biocatalysts.
The implications of this announcement are significant for industries relying on biocatalysis, including pharmaceuticals, agrochemicals, food, fine chemicals, and personal care. In pharma, AI biocatalysis is already enabling asymmetric synthesis of chiral intermediates and replacing hazardous reagents with cleaner routes. Agrochemicals are using it to fine-tune toxicology profiles, while the food industry benefits from cleaner labels through enzymatic modification. Fine chemicals and personal care are exploring high-value conversions and milder, more sustainable processes. By reducing development time and costs, and enabling access to previously inaccessible molecules, Creative Enzymes' platform could accelerate the adoption of biocatalysis across multiple sectors, fostering greener and more efficient manufacturing practices.
